A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer.

STAMPEDE2 is a trial testing new treatments in men with prostate cancer that has spread to other parts of the body (metastatic prostate cancer). It tests these treatments when the cancer is hormone-sensitive, which means that it is responsive to treatment with hormone therapy. STAMPEDE2 is a set of three randomised controlled trials (called comparisons) testing the addition of three new treatments to the standard-of-care.


For more information, please see the STAMPEDE2 trial page or visit the website:

STAMPEDE2 trial page

STAMPEDE2 trial website